Key result
Factor V Leiden mutation was not associated with an increased risk of left ventricular thrombus formation in patients with acute myocardial infarction.
Why the study?
Does the Factor V Leiden mutation increase the risk of left ventricular thrombus formation in patients with acute myocardial infarction?
Observational (n=230)
Does the Factor V Leiden mutation increase the risk of left ventricular thrombus formation in patients with acute myocardial infarction?
The Factor V Leiden mutation is not a significant risk factor for the formation of left ventricular thrombus following an acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Factor V Leiden does not predict post-AMI LV thrombus; leaves open confirmation in larger prospective cohorts.
OBJECTIVE: The genetic defect of coagulation factor V, known as factor V Leiden, produces a resistance to degradation by activated protein C (APC) and increases the risk of venous thrombosis. However, the role of factor V Leiden in the formation of left ventricular (LV) thrombus has not been studied. We investigated whether factor V Leiden is a risk factor for LV thrombus in patients with acute myocardial infarction (AMI). METHODS AND RESULTS: We have analyzed clinical, echocardiographic and biochemical data in 135 consecutive patients (aged 58 +/- 13 years; 31 women) with first anterior AMI. Two-dimensional echocardiographic examination was performed on days 1, 3, 7, 15 and 30; LV thrombus was detected in 33 (24.4%) of 135 patients with AMI. The study also included 95 control subjects. Healthy age and sex-matched subjects without a personal or family history of ischaemic heart disease, stroke or thromboembolic disease served as a control group. Blood samples from the patients and controls were analyzed for the factor V Leiden mutation by DNA analysis, using the polymerase chain reaction. In addition, concentrations of fibrinogen, von Willebrand factor (vWF), tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1) and D-dimer were measured in 135 patients. There was no significant difference in the prevalence of factor V Leiden between patients and control subjects. The prevalence of the factor V mutation was 9% (3/33) in patients with thrombus, and 7.7% (8/103) in patients without thrombus. The prevalence of factor V Leiden was 7.3% (7/95) in control subjects. No significant differences in plasma fibrinogen (480 +/- 195 vs. 444 +/- 179 mg/dl, p = 0.6), D-dimer (471 +/- 256 vs. 497 +/- 293 ng/dl, p = 0.7), vWF (112 +/- 18 vs. 103 +/- 15%, p=0.5), PAI-1 (26.7+/- 9.8 vs. 28.1 +/- 10.2 ng/dl, p = 0.6), and t-PA (19.8 +/- 8.7 vs. 17.2 +/- 9.1 ng/dl, p = 0.7), levels are found in patients with LV thrombus when compared with those without LV thrombus. Multivariate analyses showed that peak creatine kinase level (p = 0.002) and LV wall motion score index (p = 0.003) were independent predictors of LV thrombus formation. CONCLUSION: Factor V Leiden mutation is not a risk factor for LV thrombus formation in patients with AMI.
No takes yet. Share an insight, caveat, or question.
ÇELIK et al. (2001) conducted an observational in Acute myocardial infarction (n=230). Factor V Leiden mutation vs. Absence of Factor V Leiden mutation was evaluated on Left ventricular thrombus formation. Factor V Leiden mutation was not associated with an increased risk of left ventricular thrombus formation in patients with acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: